Saturday 17 October 2026 Export CTSO’s income statement to Excel — free account

Cytosorbents Corporation

Cytosorbents Corporation’s revenue for fiscal 2025 (year ended December 2025) was $37.1 million, up 4.12% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 333.3%, free cash flow grew 64.9% and total debt rose 19.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

4.11 1.05 +34.31%

Follow CTSO

Alert me

Market cap: $9.7M
P/E: 0.0×
Fwd P/E: −2.5×
Dividend yield: —
F-score: 3/9
Altman Z: −9.24
Beneish M: −2.11
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.27

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	2	—	—	4	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 13.70%

Capital & Financial Ratios $m

Market Cap 9.65

Revenue 37.22

Net Income (18.21)

Free Cash Flow (9.42)

Net Debt 12.83

Current Ratio 0.66

Debt/Equity (22.96)

P/E ratio 0.00

Fwd P/E (2.48)

P/S ratio 0.35

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (69.23%)

Next Y EPS Growth 79.55%

Next Y revenue growth 4.90%

Next 5Y EPS Growth 45.95%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.52%

10-year low 10-year high

EV/Sales against its own 10 years 0.52%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	14	8	6	4
Receivables	6	7	8	7
Inventory	3	3	5	4
Other	—	—	—	—
	25	22	21	16

	2023	2024	2025	Q'26
Payables	4	3	3	2
ST’ Debt	3	—	—	14
Other	—	—	—	—
	14	10	10	24

Compound Annual Growth %

	10y	5y	3y
Sales	22.70%	(2.00%)	2.23%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(3.25%)	(40.51%)	(44.95%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	9	10	—	—	—
’25	9	10	9	9	37
’24	9	9	9	9	36
’23	9	9	9	3	31
’22	9	8	8	9	35
’21	11	12	10	11	43
’20	9	10	11	12	41

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(3)	(2)	(3)	(5)	(12)
’24	(5)	(5)	(2)	(2)	(14)
’23	(3)	(7)	(5)	(6)	(22)
’22	(8)	(8)	(7)	(5)	(28)
’21	(2)	(2)	(4)	(5)	(14)
’20	(3)	2	(3)	(1)	(6)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(4)	(2)	(3)	(5)	(13)
’24	(5)	(5)	(3)	(2)	(15)
’23	(4)	(7)	(5)	(7)	(23)
’22	(9)	(13)	(7)	(6)	(35)
’21	(3)	(3)	(5)	(7)	(18)
’20	(4)	1	(4)	(1)	(7)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.60)	(1.40)	—	—	—
’25	(0.40)	0.60	(1.00)	(1.80)	(2.60)
’24	(2.40)	(1.60)	(0.80)	(2.80)	(7.60)
’23	(3.40)	(2.80)	(4.20)	(2.40)	(12.80)
’22	(4.20)	(5.00)	(5.60)	(0.35)	(15.00)
’21	(2.00)	(2.20)	(3.00)	(4.20)	(11.40)
’20	(2.00)	(1.60)	(0.40)	0.00	(4.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	62.20	66.00	129.00	69.80	72.00	77.60	20.60	18.22	14.00	12.00	Analyst estimates 2026–2028 Powerpack
	High	138.00	141.00	299.00	176.40	234.80	233.68	86.60	91.80	31.80	32.20
People
People	Employees	65	84	125	153	195	221	198	186	149	129
	Revenue/emp, $m	0.15	0.18	0.18	0.16	0.21	0.20	0.18	0.17	0.24	0.29
Income, $m
Income, $m	Revenue	10	15	23	25	41	43	35	31	36	37
	Gross margin, %	58.50	63.58	66.72	70.48	73.05	74.41	59.77	70.62	69.92	71.48
	EBT	(12)	(9)	(18)	(20)	(9)	(25)	(34)	(30)	(22)	(9)
	EBT margin, %	(126.81)	(60.31)	(79.23)	(81.60)	(21.86)	(58.60)	(97.74)	(96.70)	(62.96)	(23.20)
	Net income	(12)	(8)	(17)	(19)	(8)	(25)	(33)	(29)	(21)	(8)
	Depreciation	0	0	0	1	1	1	1	2	2	2
Per share, $
Per share, $	Revenue	7.49	10.97	14.65	15.47	21.13	19.91	15.92	13.92	13.08	11.91
	Earnings	(9.40)	(6.40)	(11.20)	(12.00)	(4.00)	(11.40)	(15.00)	(12.80)	(7.60)	(2.60)
	Cash flow	(5.29)	(4.68)	(7.06)	(10.39)	(2.89)	(6.46)	(12.96)	(9.70)	(5.30)	(3.98)
	Capex	(0.47)	(1.22)	(0.99)	(0.94)	(0.86)	(1.97)	(2.96)	(0.42)	(0.25)	(0.13)
	Free cash flow	(5.76)	(5.89)	(8.05)	(11.33)	(3.76)	(8.43)	(15.92)	(10.12)	(5.55)	(4.11)
	Book value	1.05	7.43	11.03	2.12	40.81	28.86	16.24	10.52	4.08	1.90
	Shares, m	1	1	2	2	2	2	2	2	3	3
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	15.08	11.94	11.03	4.98	7.55	4.21	2.29	1.54	1.39	1.07
	P/B	107.44	17.62	14.66	36.33	3.91	2.90	2.24	2.03	4.46	6.74
	EV/Sales	15.05	11.45	10.48	5.09	5.83	3.32	1.80	1.24	1.62	1.42
	EV/FCF	(19.57)	(21.32)	(19.08)	(6.95)	(32.79)	(7.84)	(1.79)	(1.71)	(3.83)	(4.12)
Cash, $m
Cash, $m	Operating cash flow	(7)	(6)	(11)	(17)	(6)	(14)	(28)	(22)	(14)	(12)
	Capex	(1)	(2)	(2)	(2)	(2)	(4)	(6)	(1)	(1)	0
	Free cash flow	(7)	(8)	(12)	(18)	(7)	(18)	(35)	(23)	(15)	(13)
Balance, $m
Balance, $m	Working capital	4	13	21	11	72	51	24	11	12	11
	Total debt	5	10	10	15	1	14	5	5	14	17
	Net debt	0	(7)	(12)	3	(70)	(38)	(17)	(9)	6	10
	Shareholders’ equity	1	10	17	3	79	63	35	23	11	6
Returns, %
Returns, %	ROA	(112.31)	(52.05)	(59.04)	(62.57)	(13.36)	(27.37)	(42.96)	(50.34)	(41.30)	(17.91)
	ROIC	(715.47)	(209.74)	(216.12)	(190.11)	(73.46)	(58.59)	(107.43)	(138.73)	(61.12)	(56.48)
	ROE	(246.41)	(151.66)	(126.57)	(189.32)	(18.97)	(34.64)	(67.00)	(99.38)	(119.80)	(96.39)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RBOT Vicarious Surgical Inc.	$14.3M	— (loss-making)	—	—	n/m	+47.33% (above 0%: growing)	0.00%	0.00%	Compare
SINT SINTX TECHNOLOGIES, INC.	$13.4M	— (loss-making)	— (loss-making)	+199.34% (above 0%: growing)	n/m	−38.60% (below 0%: shrinking)	61.50%	(638.94%)	Compare
PETV PetVivo Holdings, Inc.	$12.9M	— (loss-making)	— (loss-making)	+13.48% (above 0%: growing)	n/m	+40.13% (above 0%: growing)	66.14%	(476.54%)	Compare
BTCY Biotricity Inc.	$10.9M	— (loss-making)	— (loss-making)	+10.40% (above 0%: growing)	n/m	+235.83% (above 0%: growing)	82.55%	3.70%	Compare
CTSO Cytosorbents Corporation	$9.7M	— (loss-making)	— (loss-making)	+0.17% (above 0%: growing)	n/m	+64.90% (above 0%: growing)	73.18%	(27.39%)
NMTC NeuroOne Medical Technologies Corporation	$9.5M	— (loss-making)	— (loss-making)	+16.33% (above 0%: growing)	n/m	+26.91% (above 0%: growing)	59.94%	(122.87%)	Compare
BMRA Biomerica, Inc.	$8.6M	— (loss-making)	11.4×	+16.96% (above 0%: growing)	n/m	−35.05% (below 0%: shrinking)	(7.88%)	(174.77%)	Compare
AEMD Aethlon Medical, Inc.	$8.5M	— (loss-making)	— (loss-making)	+335.00% (above 0%: growing)	n/m	−11.13% (below 0%: shrinking)	0.00%	0.00%	Compare
TNON Tenon Medical, Inc.	$7.8M	— (loss-making)	— (loss-making)	+126.77% (above 0%: growing)	n/m	−21.78% (below 0%: shrinking)	63.64%	(262.24%)	Compare
Median of peers	$10.2M	—	—	+16.96%	—	+7.89%	60.72%	(148.82%)

All 149 Medical Devices stocks →

Cytosorbents Corporation (CTSO) key facts

Strength: Cytosorbents Corporation’s revenue for fiscal 2025 (year ended December 2025) was $37.1 million, up 4.12% from fiscal 2024.
Cytosorbents Corporation (CTSO) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CTSO traded at $4.11, a market capitalization of $9.7 million.
Return on equity was −96.4% and debt-to-equity -22.96.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −9.24 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.